Mark Lakshmanan

7.4k total citations · 1 hit paper
54 papers, 2.5k citations indexed

About

Mark Lakshmanan is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Mark Lakshmanan has authored 54 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Endocrinology, Diabetes and Metabolism, 22 papers in Molecular Biology and 7 papers in Surgery. Recurrent topics in Mark Lakshmanan's work include Diabetes Treatment and Management (19 papers), Metabolism, Diabetes, and Cancer (16 papers) and Estrogen and related hormone effects (6 papers). Mark Lakshmanan is often cited by papers focused on Diabetes Treatment and Management (19 papers), Metabolism, Diabetes, and Cancer (16 papers) and Estrogen and related hormone effects (6 papers). Mark Lakshmanan collaborates with scholars based in United States, Canada and South Africa. Mark Lakshmanan's co-authors include Fady T. Botros, Katherine R. Tuttle, Brian Rayner, Alan G. Zimmermann, Robert S. Busch, J Robbins, Charles Atisso, Richard F. Arakaki, Thomas Blevins and Carol Wysham and has published in prestigious journals such as Circulation, American Journal of Psychiatry and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Mark Lakshmanan

53 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

2018 460 citations Mark Lakshmanan et al. profile →

Peers

Countries citing papers authored by Mark Lakshmanan

Since Specialization

Citations

This map shows the geographic impact of Mark Lakshmanan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lakshmanan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lakshmanan more than expected).

Fields of papers citing papers by Mark Lakshmanan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lakshmanan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lakshmanan. The network helps show where Mark Lakshmanan may publish in the future.

Co-authorship network of co-authors of Mark Lakshmanan

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lakshmanan. A scholar is included among the top collaborators of Mark Lakshmanan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lakshmanan. Mark Lakshmanan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes 2022 ·Cardiovascular Diabetology ·Hertzel C. Gerstein, (unknown), (unknown), Jan Basile, Ignacio Conget, William C. Cushman, Gilles R. Dagenais, Edward Franek, Mark Lakshmanan, Fernando Laņas, Lawrence A. Leiter, Nana Pogosova, Jeffrey L. Probstfield, Peter Raubenheimer, Matthew C. Riddle, Jonathan E. Shaw, Wayne Huey‐Herng Sheu, Theodora Temelkova‐Kurktschiev, (unknown), Denis Xavier	10
2	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND 2021 ·Cardiovascular Diabetology ·Маниге Кониг, Matthew C. Riddle, Helen M. Colhoun, Kelley R. Branch, Charles Atisso, Mark Lakshmanan, Reema Mody, Sohini Raha, Hertzel C. Gerstein	42
3	Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial 2020 ·European Heart Journal ·Giulia Ferrannini, Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, Raphael Diaz, Leanne Dyal, Mark Lakshmanan, Linda Mellbin, Jeffrey L. Probstfield, Matthew C. Riddle, Jonathan E. Shaw, Lars Rydén	1
4	Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States 2019 ·Diabetes Obesity and Metabolism ·Kristina S. Boye, Matthew C. Riddle, Hertzel C. Gerstein, Reema Mody, Luis‐Emilio García‐Pérez, Chrisanthi A. Karanikas, Maureen J. Lage, Jeffrey S. Riesmeyer, Mark Lakshmanan	29
5	Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the AWARD ‐1 and AWARD ‐3 clinical trials 2015 ·Diabetes Obesity and Metabolism ·Matthew Reaney, Miao Yu, Mark Lakshmanan, V. Pechtner, Kate Van Brunt	26
6	Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1) 2014 ·Diabetes Care ·Carol Wysham, Thomas Blevins, Richard F. Arakaki, (unknown), Pedro García, Charles Atisso, (unknown), Mark Lakshmanan	321
7	The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures 2011 ·Osteoporosis International ·Peyman Hadji, José Zanchetta, Luis Augusto Tavares Russo, Christopher Recknor, Kenneth G. Saag, Fergus E. McKiernan, Stuart L. Silverman, Jahangir Alam, Russel Burge, John H. Krege, Mark Lakshmanan, Daniel N. Masica, Bruce Mitlak, John L. Stock	98
8	Carnitine Is a Naturally Occurring Inhibitor of Thyroid Hormone Nuclear Uptake 2000 ·Thyroid ·Salvatore Benvenga, Mark Lakshmanan, Francesco Trimarchi	29
9	Healthcare Use among U.S. Women Aged 45 and Older: Total Costs and Costs for Selected Postmenopausal Health Risks 1999 ·Journal of Women s Health & Gender-Based Medicine ·Thomas J. Hoerger, K Downs, Mark Lakshmanan, Richard C. Lindrooth, Leo Plouffe, Brett Wendling, (unknown), Robert L. Ohsfeldt	62
10	Mobilization of Mg ²⁺ from Rat Heart and Liver Mitochondria following the Interaction of Thyroid Hormone with the Adenine Nucleotide Translocase 1996 ·Thyroid ·Andrea Romani, (unknown), Mark Lakshmanan	10
11	Effects of dexamethasone on L‐type calcium currents in the A7r5 smooth muscle‐derived cell line 1993 ·FEBS Letters ·Carlos A. Obejero‐Paz, Mark Lakshmanan, (unknown), Antonio Scarpa	9
12	Differential effect of a new thyromimetic on triiodothyronine transport into myoblasts and hepatoma and neuroblastoma cells 1992 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Mark Lakshmanan, Edison Gonçalves, Alfredo Pontecorvi, Jacob Robbins	17
13	The Transport of Thyroxine into Mouse Neuroblastoma Cells, NB41A3: The Effect of L-System Amino Acids* 1990 ·Endocrinology ·Mark Lakshmanan, Edison Gonçalves, (unknown), Daniela Foti, J Robbins	60
14	Thyroid hormone transport in a human glioma cell line 1990 ·Molecular and Cellular Endocrinology ·Edison Gonçalves, Mark Lakshmanan, Alfredo Pontecorvi, J Robbins	18
15	CHANGES IN BLOOD PRESSURE AND PLASMA NORADRENALINE IN SHORT‐TERM HYPOTHYROIDISM 1989 ·Clinical Endocrinology ·Robert T. Brown, Mark Lakshmanan, (unknown), Ronald J. Polinsky	4
16	Thoracic stimulation and prolactin secretion 1989 ·Journal of Endocrinological Investigation ·Leonard P. Kapcala, Mark Lakshmanan	3
17	Different Intracellular and Intranuclear Transport of Triiodothyronine Enantiomers in Rat Skeletal Myoblasts* 1988 ·Endocrinology ·Alfredo Pontecorvi, Mark Lakshmanan, Jacob Robbins	10
18	Hindsight Bias: An Impediment to Accurate Probability Estimation in Clinicopathologic Conferences 1988 ·Medical Decision Making ·Neal V. Dawson, Hal R. Arkes, (unknown), (unknown), Mark Lakshmanan, Mary Petrelli	73
19	Intracellular Transport of 3,5,3′-Triiodo-L-Thyronine in Rat Skeletal Myoblasts* 1987 ·Endocrinology ·Alfredo Pontecorvi, Mark Lakshmanan, Jacob Robbins	25
20	Effective Low Dose Tricyclic Antidepressant Treatment for Depressed Geriatric Rehabilitation Patients: A Double‐Blind Study 1986 ·Journal of the American Geriatrics Society ·Mark Lakshmanan, Lorraine C. Mion, J. Dermot Frengley	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact